Background Wound necrosis is a potentially devastating complication of complex knee reconstruction. Laserassisted indocyanine green angiography (LA-ICGA) is a technology that has been described in the plastic surgery literature to provide an objective assessment of skin perfusion in the operating room. This novel technology uses a plasma protein bound dye (ICG) and a camera unit that is calibrated to view the frequency emitted by the dye.
surgery service. The perfusion of skin and soft tissue coverage was evaluated intraoperatively for all patients with the LA-ICGA system, and the information was used to guide wound management. Followup was at a mean of 9 months (range, 6-17 months) , no patients were lost to followup, and the main study endpoint was uneventful healing of the surgical incision. Results All seven closures went on to heal without necrosis. One patient, however, was subsequently revised for a deep periprosthetic infection 4 months after their knee reconstruction and underwent flap coverage at the time of that revision. Conclusions Implementation of LA-ICGA provides an objective intraoperative assessment of soft tissue perfusion. This technology may help guide the surgeon's decisions about wound closure in real-time to accommodate the perfusion challenges unique to each patient. Specifically, patients with medical risk factors for poor perfusion or wound healing (such as diabetes, peripheral vascular disease, tobacco use, corticosteroid therapy, infection) or anatomical/ surgical risk factors (ie, previous surgery about the reconstruction site, trauma wounds, or reconstruction of severe deformity) may benefit from objective intraoperative information regarding perfusion of the wound site. Furthermore, LA-ICGA could be used to prospectively evaluate the physiologic impact of different wound closure techniques.
Level of Evidence
Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.
Introduction
Wound necrosis is a devastating complication after TKA. Risk factors for a wound problem include previous surgery about the knee as well as a host of medical comorbidities including diabetes mellitus, obesity, vascular disease, immunosuppressive therapy, smoking, and current or recent infection [20, 21] . Prevention is important in these patients and includes measures like proper choice of skin incision, gentle handling of the soft tissues, meticulous hemostasis, and wound closure without excessive tension [4] . All of these factors and preventive measures are based on the concept that skin perfusion must be robust to avoid a wound complication [17] . Clinical judgment based on visual inspection is the most common method for evaluating blood supply but is subjective and often unreliable [23] . A variety of technologies exist to assess blood supply clinically including Doppler or CT/MR angiography; however, none has gained acceptance as a pragmatic option in reconstructive surgery for use in the operating room [5] .
Laser-assisted indocyanine green angiography (LA-ICGA) is a vascular imaging technology that can intraoperatively assess perfusion of the skin and soft tissues. This novel technology uses a plasma protein bound dye (ICG) and a camera unit that is calibrated to view the frequency emitted by the dye.
The real-time visualization of blood flow to skin and soft tissue made possible by LA-ICGA allows surgeons to tailor closure or coverage of the surgical site to meet the anticipated problem, potentially avoiding soft tissue reconstruction while preventing skin necrosis or wound breakdown after primary closures. LA-ICGA systems have existed for decades as a tool in ophthalmology and recently plastic surgery [23] . There are many features of this technology that make it appealing for evaluation of soft tissue perfusion in the surgical patient. Most importantly, it provides immediate qualitative and quantitative measurement of blood supply that can be correlated with successful wound healing [3, 8, 10, 14, 23] . The equipment needed to perform LA-ICGA is user-friendly and minimally disruptive to operative flow. Importantly, the ICG dye needed for assessment has an excellent safety profile and a short halflife allowing the surgeon multiple evaluations during a single procedure [5, 23] . Given the experience of other specialties, LA-ICGA has potential application in orthopaedic reconstruction for patients with higher risk of poor wound healing. However, to our knowledge, the use of LA-ICGA has never been described in an orthopaedic setting.
We therefore sought to evaluate perfusion borders and tension ischemia in a series of complex knee reconstructions to guide wound management.
Patients and Methods
This investigation is a series of seven selected patients who underwent complex knee reconstruction at the Mayo Clinic, Rochester, MN, USA, from 2011 to 2013; this represents all of the patients in whom the LA-ICGA system under study was used during that time period. All were considered high risk for wound necrosis or need of fasciocutaneous flap coverage as a result of scarring from previous procedures, presence of infection, or medical comorbidities. There were five males and two females with an age range of 51 to 68 years. Three patients in the group underwent complex primary TKA, two had resection of an infected TKA, and two underwent reimplantation of a previously infected TKA. Each patient in this group had multiple risk factors for wound healing complications, including prior surgery on the knee, previous wound breakdown, infections (active or prior), smoking, morbid obesity, and/or medical conditions associated with poor wound healing ( Table 1) .
LA-ICGA Imaging System
The SPY Elite 1 fluorescent imaging system (LifeCell Corporation, Branchburg, NJ, USA) was used in this series to assess perfusion of soft tissues about the knee in real-time. The LA-ICGA system consists of an imaging head that contains a charge-coupled device (CCD) camera, a laser light source, and a distance sensor. The laser operates at a power density of 40 mW/cm 2 , well below the threshold of 200 mW/cm 2 where tissue damage can occur [6] . The CCD camera is attached to the mobile central processing unit by an arm with multiple points of articulation to allow positioning at a variety of angles ( Fig. 1) .
The LA-ICGA camera is calibrated to recognize the fluorescence of ICG, a water-soluble dye with a peak absorption of 800 to 810 nm in blood. ICG can be injected intravenously after it is reconstituted in sterile water. The dye rapidly binds to plasma proteins and is taken up almost exclusively by hepatic parenchymal cells with a half-life of approximately 5 minutes.
To obtain accurate measurements, all dressings must be removed from the skin before imaging. A sterile drape must be placed over the camera head and arm of the device to safely position it over the patient. The camera head is equipped with two red lasers that converge to a single point once optimal distance from the patient's skin has been achieved [12] . This feature ensures a high-quality image that is reproducible and standardized between cases.
Once the camera is in place and all tourniquets or blood pressure cuffs have been let down, the anesthesiologist can inject the ICG. The dye is prepared as a 25-mg powder that is reconstituted in 10 cc of sterile water for a final concentration of 2.5 mg/mL. A full dose of dye is 5 cc, allowing for two administrations per batch. The anesthesiologist pushes 5 cc of dye followed by a 10-cc saline flush after which time the operating room lights must be shut down immediately [12] . The ICG takes approximately 15 seconds to reach the knee. At this point, the camera can be left stationary or moved freely to assess perfusion of the soft tissues in real-time. The resultant image is scaled black and white with darker areas representing lower perfusion and brighter zones indicating higher perfusion. The LA-ICGA system used in this investigation is also capable of quantifying the brightness of up to 30 points simultaneously on a scale from 0 to 255 units, which enhances objectivity and reproducibility between cases. An example of imaging with the LA-ICGA can be seen in Video 1 (Available as supplemental material in the online version of CORR 1 ). For the purposes of this study, the qualitative images provided by the LA-ICGA system were used to determine (1) tissue viability of native skin and fasciocutaneous flaps;
(2) perfusion barriers from previous surgery for planning new incisions; and (3) the presence of tension ischemia along the closure border (Table 1) .
In patients with significant previous surgical scar or flap coverage, the information was used to assess perfusion about the knee before and during incision and exposure. Visualizing the soft tissue perfusion in real-time enabled more precise navigation around vulnerable areas to ensure that the most robustly perfused skin would be used for wound closure. At the conclusion of the procedures, LA-ICGA allowed for identification of poorly perfused zones. If areas of skin were receiving suboptimal blood flow, the closure was revised often by releasing sutures causing tension ischemia to the vulnerable tissue. Furthermore, LA-ICGA allowed for objective inspection of flap integrity to assess if the coverage was at risk of necrosis and breakdown.
Followup was at a mean of 9 months (range, 6-17 months), no patients were lost to followup, and the main study endpoint was uneventful healing of the surgical incision.
Results
Use of the LA-ICGA system altered management in each of the procedures in which we used it (Table 1) . Preoperatively, the need for a flap was deemed highly likely; however, that intervention was successfully avoided for each patient. All seven patients, two of whose knees included previous flap coverage, had perfusion of final closure assessed to ensure tissue viability before concluding the procedure (Fig. 2) . In five patients, LA-ICGA resulted in modification of a planned initial dissection (Fig. 3) . In four patients, LA-ICGA revealed ischemia caused by undue tension at the time of wound closure relieved by modification of suture placement (Video 1, available as supplemental material in the online version of CORR 1 ).
The incision of each patient healed without necrosis; however, one patient did require two subsequent procedures. The first was for evacuation of a hematoma 2 weeks after knee reconstruction and the second for deep periprosthetic infection 4 months after knee reconstruction. The patient underwent flap coverage at the time of the second procedure as a result of the extensive débridement required to successfully manage the infection.
Discussion
Wound necrosis presents a significant challenge in complex reconstructive knee surgery. Medical comorbidities, poor preprocedure planning, and improper intraoperative management of soft tissue can lead to a devastating result for the patient [4, 18] . Most surgeons rely on clinical judgment to assess tissue viability; however, this subjective valuation can be unreliable and lead to unexpected poor outcomes. LA-ICGA is a technology with a growing body of evidence, predominantly in the plastic surgery literature, that has demonstrated use as an objective system for analyzing soft tissue blood flow in real-time [1-3, 7-15, 19, 22] . Based on these reports, it seems possible that this system could have value in orthopaedic reconstruction. Nevertheless, to our knowledge, its use has never been reported in the orthopaedic literature. We therefore sought to evaluate perfusion borders and tension ischemia in a series of complex knee reconstructions to guide optimal wound management.
This study has multiple limitations, most notably that it is a small clinical series of selected patients. Our purpose is to present this technology simply as a proof of concept for potential use in orthopaedic surgery. The study should be interpreted only after acknowledging important sources of bias, notably patient selection and surgeon self-assessment of the clinical results. The cohort was chosen as a sample of convenience in patients in whom plastic surgery consultation believed the system could enhance surgical management. Unfamiliarity with the technology was the primary reason that only seven patients were accrued over the study period; however, positive early results are increasing the indications for the system at our institution, which we will report in future studies. Another issue relates to the surgeon evaluating his or her own work. Each operation was altered because of information provided by LA-ICGA, but the measureable benefits of the subsequent adjustments remain unclear. Furthermore, this series lacks a control group. Without a control group, we do not know the degree to which overall morbidity can be avoided (or might be added) through the use of this technology. All seven patients would have been candidates to receive a flap in our practice had we not used the LA-ICGA technology; however, it is worth noting that one of the seven underwent a flap as part of a later procedure related to infection 4 months after the operation performed in this series. Controlled trials are called for to rigorously assess the use of this technology in patient care. A final important limitation is that only qualitative data were assessed. The system used at our institution is also capable of quantifying perfusion in an absolute or relative fashion, which is a potential source of investigation for future studies.
Although not a limitation per se, it is important to note that this technology is relatively new. To our knowledge, the LA-ICGA system used in this investigation is the only FDA-approved device at this time. Variations of the technology are currently used in Japan and Europe that may enter the US market at some time in the future. The retail cost of our LA-ICGA system is USD 300,000 with rental and pay-per-use options available from the manufacturer. In addition, the retail cost of the custom-fit sterile drape kit and ICG dye is USD 795 per patient. Each practice will have to evaluate this economic impact within its own patient population.
In this series, LA-ICGA altered or determined management in each of the seven procedures performed. Contributions to each procedure included mapping of dissection and exposure to navigate perfusion barriers dictated by scar tissue and previous flap coverage, revision of wound closure to reestablish robust perfusion, and confirmation of global perfusion before concluding the procedure (Table 1) . Although this series lacks a control group, the preoperative expectation was that each of these patients would require a flap at the time of wound closure or potentially shortly after periprosthetic infection 4 months after knee reconstruction necessitated flap coverage for adequate closure. Our initial experience is consistent with that reported in numerous case series and prospective studies in the plastic surgery literature in which intraoperative, objective assessment of perfusion with LA-ICGA decreased rates of postoperative necrosis in comparison to clinical judgment alone [1-3, 5, 7, 8, 10, 11, 13, 14, 19, 23] .
Future directions for study may include the use of LA-ICGA in a variety of orthopaedic reconstruction settings. Specifically, patients with medical risk factors for poor perfusion or wound healing (ie, diabetes, peripheral vascular disease, tobacco use, corticosteroid therapy, infection) or anatomical/surgical risk factors (ie, previous surgery about the reconstruction site, trauma wounds, or reconstruction of severe deformity) may benefit from objective intraoperative information regarding perfusion of the wound site. Although this series focused on the qualitative features of the technology, quantitation is also possible. The brightness of up to 30 points can be measured simultaneously on a scale from 0 to 255 units, which enhances objectivity and reproducibility between procedures. This feature could be used to prospectively evaluate the physiologic impact of different wound closure techniques.
As many practices are treating more complex revisions, in conjunction with the increasing emphasis in healthcare policy to avoid complications, this technology has the potential to be a useful tool in orthopaedic surgery moving forward. Importantly, the technology itself places the patient at little risk. The ICG dye is secreted into the bile and is not recirculated in the enterohepatic circulation to any large degree [15] . This mechanism of elimination makes the dye safe for use in patients with renal dysfunction. ICG is nontoxic and has only had 17 reported adverse reactions in 34 years, a rate of four in every 240,000 doses [16] . Although it is considered quite safe, the dye is contraindicated in patients with iodine allergies as a result of a 5% composition of sodium iodide. In summary, LA-ICGA is a tool that provides an option for objectively assessing and managing complex wound issues. This investigation is a proof of concept that the experience reported in plastic surgery may translate to orthopaedic reconstruction. Further prospective study with control groups will be needed to thoroughly evaluate this technology moving forward.
